Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

Tyrosine kinase inhibitors (TKIs) are very efficacious in non-small-cell lung cancer (NSCLC) patients harboring activating Epidermal Growth Factor Receptor (EGFR) mutations. However, about 10% of EGFR wild type (wt) patients respond to TKI, with unknown molecular mechanisms of sensitivity. We consid...

Full description

Bibliographic Details
Main Authors: Paola Ulivi, Angelo Delmonte, Elisa Chiadini, Daniele Calistri, Maximilian Papi, Marita Mariotti, Alberto Verlicchi, Angela Ragazzini, Laura Capelli, Alessandro Gamboni, Maurizio Puccetti, Alessandra Dubini, Marco Angelo Burgio, Claudia Casanova, Lucio Crinò, Dino Amadori, Claudio Dazzi
Format: Article
Language:English
Published: MDPI AG 2014-12-01
Series:International Journal of Molecular Sciences
Subjects:
NSCLC
erlotinib
EGFR wt
p53
KRAS
Online Access:http://www.mdpi.com/1422-0067/16/1/747

Internet

http://www.mdpi.com/1422-0067/16/1/747

Similar Items